LONG

Stella and RTHM Partner to Treat Long COVID

Retrieved on: 
星期一, 六月 6, 2022
Entrepreneurship, PTSD, Sympathetic nervous system, COVID, Journal, STELLA, Knowledge, Journal of Neuroimmunology, Trauma, Microdeletion syndrome, SGB, FDA, Patient, COVID-19, Diagnosis, Population, Trauma center, Pharmaceutical industry, Fur clothing, Long COVID

CHICAGO, June 6, 2022 /PRNewswire/ -- Stella ( www.stellacenter.com ), the leader in Stellate Ganglion Block (SGB) treatment for emotional trauma and mental health management, and RTHM ( www.rthm.com ), a Long COVID clinic with expert clinicians, a research arm, and a patented treatment and diagnosis algorithm, have partnered to provide RTHM's Long COVID patients with access to Stella's Stellate Ganglion Block (SGB) treatment.

Key Points: 
  • Recently, Stella partners published a case study in the Journal of Neuroimmunology that showed how SGB treatment reduced symptoms of Long COVID.
  • "The collaboration between RTHM and Stella provides our patients with a unique and potentially helpful treatment."
  • RTHM is unpacking the knowledge gained from other, often post-viral diseases like ME/CFS and leveraging that wisdom for those suffering with Long COVID.
  • RTHM will be using apps and biological and biometric data gleaned from wearable devices, which could help support the efficacy of SGBs in people with Long COVID.

Audience Platform Is Pleased to Announce the Hiring of Long Ellis as SVP Client Strategy

Retrieved on: 
星期二, 五月 31, 2022
Technology, Other Communications, Finance, Publishing, Marketing, Accounting, Communications, Professional Services, Data Management, MBA, Economics, Williams College, Columbia Business School, CBS, Solution, BA, Comedy Central, Vizio, Viacom, Google TV, Audience, Varsity team, Awareness, Ali Baba, Organization, AP, Adoption, Yahoo!, CTV, Data management, Google, Mobile phone, Marketing

Long brings extensive experience in ad tech, advanced TV, CTV, data management, yield optimization and programmatic capabilities and is a key addition to our senior management team.

Key Points: 
  • Long brings extensive experience in ad tech, advanced TV, CTV, data management, yield optimization and programmatic capabilities and is a key addition to our senior management team.
  • Long then followed his passion for advancing TV technology and joined Google as Director of their Google TV Ads advanced TV division.
  • At Google, Long tripled the TV ad sales team that drove revenue from $9M to $120M in two years.
  • He and his wife Catherine, have three grown children and reside in Rowayton, CT.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005781/en/

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

Retrieved on: 
星期四, 五月 26, 2022
Health, Diabetes, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, FAQ, Risk, U.S. Securities and Exchange Commission, Regulation Fair Disclosure, Company, Disease, Private Securities Litigation Reform Act, NASH, Disclosure, Patient, File, Review, Therapy, Emms, COVID-19, Fatty liver disease, Regulation, FDA, Securities Act of 1933, Recurrence, IND, Partnership, Program, John Radcliffe Hospital, Safety, Compte rendu, EMM, British Heart Foundation, Degenerative disease, SEC, COVID, Security (finance), Fatigue, University of Oxford, CEO, Pharmaceutical industry, OHE, Long COVID

The company is suspending its Phase 2 clinical trial in OHE (Overt Hepatic Encephalopathy) while exploring potential partnership for the program.

Key Points: 
  • The company is suspending its Phase 2 clinical trial in OHE (Overt Hepatic Encephalopathy) while exploring potential partnership for the program.
  • Patient enrollment is complete in the prospective, placebo controlled, randomized trial conducted at the John Radcliffe Hospital at Oxford University in England.
  • We look forward to sharing the results of the trial given the ever growing patient need for a product to address Long COVID fatigue.
  • Bill Hinshaw, President and CEO of Axcella, continued: We are a leader in therapeutics for Long COVID and in particular addressing fatigue.

Long John Silver's Experiences a 55% Increase in Digital Sales During Lent

Retrieved on: 
星期二, 五月 24, 2022
Online, Digital, POS, Social media, DoorDash, Ground control, Meat, Order, Long John Silver's, Restaurant, Partnership, Marketing, Lent, Revolution, Instagram, Human, Sale, Connect, LinkedIn, Twitter, LLC, CEO, Video game, Airline, Online shopping, Facebook

SOUTHLAKE, Texas, May 24, 2022 /PRNewswire-PRWeb/ -- Today, Restaurant Revolution Technologies (Revolution) announced that its Order One digital ordering platform and Connect marketplace insertion product powered a 55% increase to restaurant chain partner, Long John Silver's, average daily revenue related to digital orders during the 2022 Lent season. The 2022 season is the first Lent season the iconic brand engaged customers through digital solutions like website online ordering for pickup and delivery.

Key Points: 
  • The 2022 season is the first Lent season the iconic brand engaged customers through digital solutions like website online ordering for pickup and delivery.
  • Long John Silver's, the nation's largest quick-service seafood chain, also experienced a 48% increase to its average daily digital order volume as well as a 5% increase to its average daily digital ticket when compared to the average daily digital order volume and tickets prior to the season.
  • "We're looking to continue our digital transformation success by implementing plans related to delivery, online promotions and fully utilizing the Order One platform's marketing tools to continue serving the best Long John Silver's digital experience."
  • By year's end, numerous Long John Silver's franchisees were added, too, with more of the brand's system continuing implementation in 2022.

Axcella Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
星期四, 五月 5, 2022
Health, Diabetes, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, D, COVID-19, Private Securities Litigation Reform Act, Regulation Fair Disclosure, File, IND, Compte rendu, Emms, Regulation, Securities Act of 1933, Physician, Research, Disclosure, Patient, Security (finance), Review, Recurrence, FDA, FAQ, U.S. Securities and Exchange Commission, NASH, Fatty liver disease, EMM, SEC, Homeostasis, OHE, Risk, Therapy, Pharmaceutical industry, Long COVID

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.
  • Axcella expects that its current cash balance will be sufficient to meet its operating needs into 2023.
  • Net Loss: Net loss for the quarter ended March 31, 2022 was $19.0 million, or $0.46 per basic and diluted share.
  • Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs).

Truist acquires mobile savings gamification pioneer Long Game

Retrieved on: 
星期二, 五月 3, 2022
Momentum, Workplace, Innovation, Economics, Investment, Gen, Insurance, Alston & Bird, Truist Financial, Generation Z, FDIC, NYSE, Consumer Technology Association, TFC, CA, Holden, CIO, The Long Game, Small business, Mark (given name), View, Solution, Technology, Growth, Acquisition, Multimedia, Renewable energy, Creative industries, Bank

CHARLOTTE, N.C., May 3, 2022 /PRNewswire/ -- Truist Financial Corporation (NYSE: TFC) today announced it has acquired Long Game, the award-winning gamified finance mobile app that is changing the way people save, learn and engage with their finances. Long Game transforms how users engage with their bank by using prize-linked savings and casual gaming to motivate smart financial behaviors and driving new account growth and client retention for banks. Truist will leverage Long Game's innovative technology to help its clients build long-term financial wellness and advance its purpose to inspire and build better lives and communities.

Key Points: 
  • Long Game transforms how users engage with their bank by using prize-linked savings and casual gaming to motivate smart financial behaviors and driving new account growth and client retention for banks.
  • "Long Game is a female-led business with a diverse team of incredibly talented innovators creating unique solutions to help people achieve financial confidence."
  • Long Game is a personal finance app that uses gamification to empower Gen-Z and millennials to develop healthy financial habits.
  • The app uses best-practices from mobile gaming, and a behavioral economics strategy called prize-linked savings, to increase savings and financial education.

Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022

Retrieved on: 
星期三, 四月 27, 2022
IC50, Monocyte, COVID-19, Research, GLOBE, Patient, Ivermectin, Technology, Breast cancer, Immune system, OTCQB, TBIA, Synthase, Cell cycle, Knowledge, Alzheimer's disease, Pressure, U.S. Securities and Exchange Commission, Cancer immunotherapy, Company, Observational study, Solution, TMB-2, Disease, Overalls, CEO, MERS, Legislation, Good, Dietary supplement, Plasma, Apoptosis, Coronavirus, Neurodegeneration, GCP, IRB, Biotechnology, Neuron, Brain, PCR, Institutional review board, Method, Â, Physician, Cancer, COVID, Lymphocyte, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Medical imaging, Long COVID

Tollovid and Tollovid Daily are not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID.

Key Points: 
  • Tollovid and Tollovid Daily are not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID.
  • Concurrent with this announcement, the Company announced that it will be offering a 50% discount on the price of Tollovid Maximum Strength through close of business on May 31st, 2022.
  • In the last year we have heard anecdotal reports from customers who have experienced great success using our dietary supplements, said Gerald E. Commissiong, President and CEO of Todos Medical.
  • Based on these, we are preparing for an observational study for Tollovid in Long COVID, and have received overwhelming interest from physicians and patients in participating.

Tealium Appoints Claire Long to Board of Directors

Retrieved on: 
星期二, 四月 26, 2022
Board, Microsoft, Data management, Marketing, LLC, Audit committee, CDP, Investor, Board of directors, Covario, Machine learning, SAN, The San Diego Union-Tribune, Ecosystem, Solution, IOT, Multimedia, Industry, Accounting, API, Time, Management, Online shopping, Tealium

SAN DIEGO, April 26, 2022 /PRNewswire/ -- Tealium, the most trusted and world's largest independent customer data platform (CDP), today announced the appointment of Claire Long to its Board of Directors as well as its Audit Committee Chair. Currently serving as the Managing Member of Long Partners, LLC and with more than 20 years of experience working as a financial executive, Long has expertise leading large teams of accounting and finance professionals.

Key Points: 
  • SAN DIEGO, April 26, 2022 /PRNewswire/ -- Tealium ,the most trusted and world's largest independent customer data platform (CDP), today announced the appointment of Claire Long to its Board of Directors as well as its Audit Committee Chair.
  • "I'm honored to join Tealium's Board of Directors," said Long.
  • "We are thrilled to welcome Claire Long as one of the newest members to our Board of Directors," said Jeff Lunsford, Chief Executive Officer at Tealium.
  • Her unique perspectives will be very valued on the Tealium Board of Directors."

Cox Media Group Announces Legal Department Changes

Retrieved on: 
星期一, 四月 25, 2022
News, CEO, Corporation, Government, CMG, Telemundo, VP, ABC, Greenberg, Associate, GLOBE, General counsel, Cox Media Group, Television, Law & Policy, EVP, NBC, CBS, FCC, MyNetworkTV, Industry, Business, FOX, Congress, Public relations, Policy

ATLANTA, April 25, 2022 (GLOBE NEWSWIRE) -- Cox Media Group (CMG) today announced the addition of longtime CBS executive Andrew J. Siegel as the new VP, Associate General Counsel - Business and Legal Affairs.

Key Points: 
  • ATLANTA, April 25, 2022 (GLOBE NEWSWIRE) -- Cox Media Group (CMG) today announced the addition of longtime CBS executive Andrew J. Siegel as the new VP, Associate General Counsel - Business and Legal Affairs.
  • These changes elevate CMGs legal breadth and depth as we partner with our media stations and help drive the companys strong vision in an ever-changing media ecosystem, Greenberg said.
  • I congratulate Eric on building a legal department that is so well-equipped to partner with our media stations and support the dynamic nature of our vision and business strategy.
  • CMG Media Corporation (d/b/a Cox Media Group) is an industry-leading media company with unparalleled brands, award-winning content, and exceptional people.

Tonix Pharmaceuticals to Participate in the NobleCon18 Investor Conference

Retrieved on: 
星期二, 四月 12, 2022
Fibromyalgia, Disease, Prader–Willi syndrome, Pain, Government, CD154, Neurology, Security (finance), U.S. Securities and Exchange Commission, COVID-19, Smallpox, Monkeypox, Tablet, Long COVID, Risk, RPV, Cocaine, Research, The Rock Hotel, Annual report, Psychiatry, Private Securities Litigation Reform Act, CNS, Central nervous system, Therapy, Severe acute respiratory syndrome coronavirus 2, Infection, Failure, Vaccine, Autoimmunity, Omicron, SEC, Hard Rock Cafe, Degenerative disease, Hydrogen chloride, SL, FDA, IR, Cancer, Pharmaceutical industry, Tonix Pharmaceuticals

About Tonix Pharmaceuticals Holding Corp.

Key Points: 
  • About Tonix Pharmaceuticals Holding Corp.
    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering.
  • A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022.
  • solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development.
  • Tonix expects to initiate a Phase 2 study in Long COVID in the first half of 2022.